SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

Manuela Mancini(Istituto di Ematologia di Bologna), Simona Soverini(University of Bologna)
Research Square
December 19, 2022
10.21203/rs.3.rs-2381244/v1
Cited by 0

Related Papers

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
|Leukemia|2017|38
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
|Biomarker Research|2023|6
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
|Cancers|2022|2